Trial Profile
Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Jun 2012
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 26 May 2012 Actual initiation date changed from Jan 2011 to 2 Feb 2011 as reported by EudraCT.
- 22 Mar 2012 New trial record